Shi, Yuankai Wu, Jianqiu Wang, Zhen Zhang, Liling Wang, Zhao Zhang, Mingzhi Cen, Hong Peng, Zhigang Li, Yufu Fan, Lei
...
Published in
Journal of Hematology & Oncology
BackgroundPeripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical benefit. We conducted this study to evaluate the efficacy and safety of geptanolimab (GB226), an anti-PD-1 antibody, in r/r PTCL patients.MethodsWe did this single-arm, multicenter phase 2 study across...
Li, Chengqiang; Zhao, Shengguang; Zheng, Yuyan; Han, Yichao; Chen, Xiaoyan; Cheng, Zenghui; Wu, Yuquan; Feng, Xijia; Qi, Weixiang; Chen, Kai;
...
BACKGROUND: To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable oesophageal squamous cell carcinoma (ESCC) (ClinicalTrials.gov number, NCT03792347). METHODS: Twenty resectable ESCC patients, regardless of programmed death ligand-1 status, received preoperative pembrolizumab with concur...
Zhang, Er-lei Zhang, Zun-yi Li, Jian Huang, Zhi-yong
Published in
OncoTargets and therapy
Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/9Hw8vlnbtNA
Xue, Wenji Zhang, Tao Wang, Xin Duan, Jianchun Bi, Nan
Published in
Journal of clinical pharmacy and therapeutics
Several immune checkpoint inhibitors (ICIs) are now available for treatment of non-small cell lung cancer (NSCLC). However, not all patients benefit from ICI therapy, and the choice of ICIs is limited. A 54-year-old man with locally advanced NSCLC achieved partial response after definitive chemoradiotherapy. When he opted for consolidation therapy,...
Liu, Xuhong Yi, Yong
Published in
Biomarker Research
In recent years, there have been advancements in traditional patterns of tumor therapy with the adoption of immunotherapy. Its application with or without other combined regimens has attracted attention from clinicians. Sintilimab (Tyvyt®), a highly selective fully human IgG4 monoclonal antibody, blocks the binding site of programmed cell death pro...
Fan, Yun Zhao, Jun Wang, Qiming Huang, Dingzhi Li, Xingya Chen, Jianhua Fang, Yong Duan, Jianchun Zhou, Caicun Hu, Yanping
...
Published in
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Treatment options in the second-line extensive-stage SCLC (ED-SCLC) setting are limited. The PASSION study (ClinicalTrials.gov identifier: NCT03417895) was a phase 2 study of camrelizumab plus apatinib in ED-SCLC after platinum-based chemotherapy. In stage I of the study, patients were randomized (1:1:1) to receive camrelizumab 200 mg every 2 weeks...
Tentler, John J. Lang, Julie Capasso, Anna Kim, Deog Joong Benaim, Ely Lee, Young B. Eisen, Andrew Bagby, Stacey M. Hartman, Sarah J. Yacob, Betelehem W.
...
Published in
BMC Cancer
BackgroundTriple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited systemic treatment options. RX-5902 is a novel anti-cancer agent that inhibits phosphorylated-p68 and thus attenuates nuclear β-catenin signaling. The purpose of this study was to evaluate the ability of β-catenin signaling blockade to enhance the eff...
Chen, Shixue Huang, Ziwei Jia, Wangping Tao, Haitao Zhang, Sujie Ma, Junxun Liu, Zhefeng Wang, Jinliang Wang, Lijie Cui, Pengfei
...
Published in
Journal of Hepatocellular Carcinoma
Purpose At present, there are no validated biomarkers that can predict whether patients with advanced hepatocellular carcinoma (aHCC) are likely to benefit from anti-PD-1 therapy. We aimed to determine whether lung immune prognostic index (LIPI) is associated with outcomes in patients with aHCC treated with PD-1 inhibitors. Patients and Methods Pat...
Al-Toubah, Taymeyah Pelle, Eleonora Strosberg, Jonathan
Published in
Oncotarget
Salamaliki, Christina Solomou, Elena E. Liossis, Stamatis-Nick C.
Published in
Rheumatology and Therapy
Immune checkpoint inhibitors are a promising new therapeutic strategy in oncology that aims to eliminate cancer cells by enhancing patients' immune response against tumor antigens. Despite their beneficial effects, immune checkpoint inhibitors are also responsible for a plethora of autoimmune manifestations, known as immune-related adverse events. ...
